Graded against 173,636 supplements + 177 published clinical interactions, sourced from PubMed, FDA CAERS, openFDA, NIH DSLD
Benfotiamine
MODERATE EVIDENCESupplementLast updated
AVELOR SUMMARY
Benfotiamine is a fat-soluble thiamine (B1) derivative with 5x greater bioavailability than regular thiamine. It blocks AGE formation (advanced glycation end products) and reduces diabetic neuropathy symptoms. A 2008 RCT found 600mg/day benfotiamine significantly reduced neuropathic pain in diabetic patients. Also prevents high-glucose damage to endothelial cells (AGE pathway blockade). Dose: 150-600mg/day. Distinct from sulbutiamine (which crosses BBB). Benfotiamine does NOT cross BBB — peripheral benefits only.
---
*Reviewed by the Dose AI Research Team and Clinical Advisory Board*
*Last updated: 2026-04-06*
Independently graded against 173,636 indexed supplements with 177 published clinical interactions, sourced from PubMed, FDA CAERS, openFDA, and NIH DSLD | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.